{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:34:42Z","timestamp":1786649682497,"version":"build-2736575974"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>The aim of this study was to report the acute toxicity, quality of life (QoL), and cosmesis in patients treated with moderate hypofractionated radiotherapy following breast-conserving surgery.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>This prospective cohort study included consecutive female breast cancer patients who underwent adjuvant moderate hypofractionated radiotherapy following breast-conserving surgery from April 2021 to October 2022. Acute toxicity was documented using the Radiation Therapy Oncology Group (RTOG) criteria and Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 (NCI). At baseline, 3 months, and 6 months, QoL was documented using the European Organization for the Research and Treatment of Cancer QoL Questionnaire (EORTC QLQ). C30 and BR-23, and cosmesis was assessed using the Harvard Cosmesis Scale.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Two hundred and eleven patients were included, among whom 149 (71%) were treated with three-dimensional conformal radiotherapy (3DCRT) and 62 (29%) with image-guided radiotherapy (IGRT). Twenty patients (9.5%) had Grade 2 skin reaction, and one patient (0.5%) had Grade 3 skin reaction. Skin toxicity was not significantly different between 3DCRT and IGRT (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.20). At baseline, the worst QoL scores were sexual function, emotional function, upset by hair loss, and fatigue. All QoL scores improved at 3 and 6 months, except the mean breast symptom score, which slightly worsened at 3 months, then improved at 6 months. The mean Global Health Status Score at baseline was 69.87 \u00b1 12.76 and improved to 85.89 \u00b1 9.45 at 6 months (P &lt; 0.001). Fourteen patients (6.6%) had a change in cosmesis to \u201cfair\u201d at 6 months.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Significant acute skin reactions are less after moderate hypofractionated breast radiotherapy, and cosmesis is good to excellent in the majority of patients. Overall QoL is not affected and is preserved after radiotherapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jcrt.jcrt_2248_24","type":"journal-article","created":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T17:00:46Z","timestamp":1767200446000},"page":"1327-1333","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Prospective cohort study on acute toxicity, quality of life, and cosmesis in patients treated with moderate hypofractionated radiotherapy following breast-conserving surgery"],"prefix":"10.4103","volume":"21","author":[{"given":"Meenu","family":"Jose","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Amrita Institute of Medical Sciences, Amrita Vishwa Vidyapeetham, Kochi, Kerala, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay","family":"Sasidharan","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Amrita Institute of Medical Sciences, Amrita Vishwa Vidyapeetham, Kochi, Kerala, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sruthi","family":"Kalavagunta","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Amrita Institute of Medical Sciences, Amrita Vishwa Vidyapeetham, Kochi, Kerala, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"DK","family":"Vijaykumar","sequence":"additional","affiliation":[{"name":"Department of Gynaecologic Oncology, Amrita Institute of Medical Sciences, Amrita Vishwa Vidyapeetham, Kochi, Kerala, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keechilat","family":"Pavithran","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Amrita Institute of Medical Sciences, Amrita Vishwa Vidyapeetham, Kochi, Kerala, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debnarayan","family":"Dutta","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Amrita Institute of Medical Sciences, Amrita Vishwa Vidyapeetham, Kochi, Kerala, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,12,31]]},"reference":[{"key":"R1-20260102","doi-asserted-by":"crossref","first-page":"209","DOI":"10.5306\/wjco.v13.i3.209","article-title":"Breast cancer in India: Present scenario and the challenges ahead","volume":"13","author":"Mehrotra","year":"2022","journal-title":"World J Clin Oncol"},{"key":"R2-20260102","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.radonc.2010.04.008","article-title":"Comparison of early quality of life in patients treated with radiotherapy following mastectomy or breast conservation therapy: A prospective study","volume":"97","author":"Munshi","year":"2010","journal-title":"Radiother Oncol"},{"key":"R3-20260102","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1055\/s-0042-1743420","article-title":"Quality of life post breast cancer surgery: Comparison of breast conservation surgery versus modified radical mastectomy in a developing country","volume":"11","author":"Cherian","year":"2022","journal-title":"South Asian J Cancer"},{"key":"R4-20260102","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1016\/S0140-6736(11)61629-2","article-title":"Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: Meta-analysis of individual patient data for 10,801 women in 17 randomised trials","volume":"378","author":"Darby","year":"2011","journal-title":"Lancet"},{"key":"R5-20260102","doi-asserted-by":"crossref","first-page":"189","DOI":"10.4103\/ijmr.IJMR_565_20","article-title":"Adjuvant radiation therapy in breast cancer: Recent advances and Indian data","volume":"154","author":"Chakraborty","year":"2021","journal-title":"Indian J Med Res"},{"key":"R6-20260102","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.radonc.2014.11.030","article-title":"ESTRO consensus guideline on target volume delineation for elective radiation therapy of early stage breast cancer","volume":"114","author":"Offersen","year":"2015","journal-title":"Radiother Oncol"},{"key":"R8-20260102","doi-asserted-by":"crossref","first-page":"20170152","DOI":"10.1259\/bjr.20170152","article-title":"First clinical report of helical tomotherapy with simultaneous integrated boost for synchronous bilateral breast cancer","volume":"90","author":"Wadasadawala","year":"2017","journal-title":"Br J Radiol"},{"key":"R10-20260102","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for research and treatment of cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"R11-20260102","first-page":"172","article-title":"Validation of EORTC quality-of-life questionnaire in Indian women with operable breast cancer","volume":"18","author":"Parmar","year":"2005","journal-title":"Natl Med J India"},{"key":"R12-20260102","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/0360-3016(79)90729-6","article-title":"Analysis of cosmetic results following primary radiation therapy for stages I and II carcinoma of the breast","volume":"5","author":"Harris","year":"1979","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R14-20260102","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4103\/jcar.JCar_26_20","article-title":"Ten-year survival outcome of breast cancer patients in India","volume":"20","author":"Viral","year":"2021","journal-title":"J Carcinog"},{"key":"R15-20260102","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.3332\/ecancer.2023.1542","article-title":"Long-term outcomes and prognostic factors in elderly patients with breast cancer: Single-institutional experience","volume":"17","author":"Wadasadawala","year":"2023","journal-title":"Ecancer"},{"key":"R16-20260102","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.breast.2021.09.008","article-title":"Unique challenges and outcomes of young women with breast cancers from a tertiary care cancer centre in India","volume":"60","author":"Bajpai","year":"2021","journal-title":"Breast"},{"key":"R17-20260102","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.clon.2011.04.011","article-title":"The cambridge breast intensity-modulated radiotherapy trial: Patient- and treatment-related factors that influence late toxicity","volume":"23","author":"Barnett","year":"2011","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"R18-20260102","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/S0140-6736(08)60348-7","article-title":"The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: A randomised trial","volume":"371","author":"Bentzen","year":"2008","journal-title":"Lancet"},{"key":"R19-20260102","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.7314\/APJCP.2014.15.6.2505","article-title":"Hypofractionated radiotherapy for breast cancers--preliminary results from a tertiary care center in eastern India","volume":"15","author":"Nandi","year":"2014","journal-title":"Asian Pac J Cancer Prev"},{"key":"R20-20260102","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.radonc.2016.02.027","article-title":"Acute skin toxicity associated with a 1-week schedule of whole breast radiotherapy compared with a standard 3-week regimen delivered in the UK FAST-Forward Trial","volume":"120","author":"Brunt","year":"2016","journal-title":"Radiother Oncol"},{"key":"R21-20260102","doi-asserted-by":"crossref","first-page":"100392","DOI":"10.1016\/j.lansea.2024.100392","article-title":"Preliminary results of hypofractionated radiotherapy in breast cancer in Chandigarh, India: Single-centre, non-inferiority, open-label, randomised, phase 3 trial","volume":"24","author":"Yadav","year":"2024","journal-title":"Lancet Reg Health Southeast Asia"},{"key":"R22-20260102","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.radonc.2022.07.003","article-title":"HYPORT adjuvant acute toxicity and patient dosimetry quality assurance results-Interim analysis","volume":"174","author":"Chakraborty","year":"2022","journal-title":"Radiother Oncol"},{"key":"R23-20260102","doi-asserted-by":"crossref","first-page":"100346","DOI":"10.1016\/j.lansea.2023.100346","article-title":"Out-of-pocket payment and financial risk protection for breast cancer treatment: A prospective study from India","volume":"24","author":"Wadasadawala","year":"2024","journal-title":"Lancet Reg Health Southeast Asia"},{"key":"R24-20260102","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1053\/ejso.2002.1403","article-title":"Late morbidity after treatment of breast cancer in relation to daily activities and quality of life: A systematic review","volume":"29","author":"Rietman","year":"2003","journal-title":"Eur J Surg Oncol"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_2248_24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T18:57:00Z","timestamp":1786647420000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_2248_24"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":21,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.4103\/jcrt.jcrt_2248_24","relation":{},"ISSN":["0973-1482","1998-4138"],"issn-type":[{"value":"0973-1482","type":"print"},{"value":"1998-4138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"2024-11-21","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-24","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}